Mr. Rashid Ahmed Bux reports

BIOMARK DIAGNOSTICS HIGHLIGHTS FISCAL YEAR 2025 ACHIEVEMENTS AND SETS BOLD STRATEGIC MILESTONES FOR 2025 - 2026

Biomark Diagnostics Inc. has summarized its fiscal year 2025 highlights and key milestones for 2025 to 2026. The company's annual financial filings are available on the SEDAR+ website and on the Canadian Securities Exchange website.

In a globally challenging funding environment for biotechnology firms, Biomark demonstrated exceptional resilience. The company successfully secured financing and strengthened investor confidence by completing a $4.26-million private placement. This financing round saw strong participation from North American and European investors, underscoring trust in Biomark's management and its execution strategy.

Investor confidence remained high throughout the year, with Biomark's share price maintaining stability and posting modest gains. This performance stands in contrast to the downward trend observed across much of the diagnostics and biotech sectors, highlighting the company's strategic position and strong fundamentals.

"Our team remained focused on disciplined execution, data-driven strategy and delivering tangible value," said Rashid Bux, Biomark's chief executive officer. "That focus earned us the continued support of investors who recognized the significance of our milestones in a tough market."

2025 fiscal year highlights by strategic pillar

Biomark's key achievements for the fiscal year are categorized below, showcasing a period of significant progress across its core strategic pillars:

Financial strength

• Raised a total of $4.26-million through a private placement;
• Secured over $365,000 in non-dilutive grant funding from partners including NRC-IRAP, Mitacs, Research Manitoba and City of Quebec;
• Achieved an 18-per-cent reduction in liabilities and maintained a lean monthly burn;
• Tripled current assets, a key metric for financial health, while preserving long-term capital.

Operational and scientific progress

• Advanced a robust pipeline of AI-powered diagnostic assays for multiple cancers, including NSCLC, breast cancer, glioblastoma and neuroendocrine tumours (NETs);
• Integrated advanced technologies, including large language models (LLMs) and multitask deep learning, to enhance the predictive power and clinical utility of its assays.

Lab certification and commercial readiness

• Initiated the ISO 15189:2022 certification process, with completion targeted for Q4 2025;
• Advanced preparations for CLIA certification, paving the way for United States commercialization by early 2026;
• Positioned to introduce its first lab-developed tests (LDTs) through a soon-to-be-accredited diagnostic facility;
• Began discussions on a U.S. reimbursement strategy to support future market entry.

Publications and thought leadership

• Published multiple high-impact studies in renowned peer-reviewed journals such as Cancers and IJMS;
• Presented key clinical data at major international conferences, including the San Antonio Breast Cancer Symposium, GPEN and USCAP;
• Contributed to collaborative translational research initiatives with leading academic and industry partners in Canada and the U.S.

Strategic collaborations

• Strengthened engagements with key partners, including AstraZeneca, the University of Maryland and Ohio State University;
• Participated in several U.S. grant submissions and supported a pan-European IHI Bridges proposal aimed at scaling early detection diagnostics;
• Initiated new relationships with U.S.-based cancer screening centres and commercial labs in Canada and other global operators.

Outlook and key milestones for 2025 to 2026

Biomark remains focused on achieving several key milestones in the coming fiscal year:

• Q2 2025: Double laboratory capacity through additional equipment installation and workflow optimization initiatives. In addition, expand the lab personnel team to support higher testing volumes and the growth of its contract research organization (CRO) services.
• Q3 2025: Completion and publication of Biomark's pivotal 6,000-patient lung cancer clinical trial.
• Q3 to Q4 2025: Launch of commercial operations for the lung cancer assay in Quebec.
• Q4 2025: Finalization of ISO 15189 certification.
• Early 2026: Secure CLIA certification and commence the U.S. diagnostic service rollout.
• Continuing: Continue to expand CRO services, the menu of lab-developed tests (LDTs) and the AI-integrated diagnostics portfolio.
• Continuing: Expand existing collaborations at key centres of excellence in the U.S. and Europe.

About Biomark Diagnostics Inc.

Biomark Diagnostics is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.